Arena Pharmaceuticals, Inc. (ARNA): Price and Financial Metrics
ARNA Price/Volume Stats
| Current price | $99.99 | 52-week high | $100.00 |
| Prev. close | $99.93 | 52-week low | $45.50 |
| Day low | $99.97 | Volume | 5,718,500 |
| Day high | $100.00 | Avg. volume | 1,561,326 |
| 50-day MA | $93.21 | Dividend yield | N/A |
| 200-day MA | $70.04 | Market Cap | 6.17B |
ARNA Stock Price Chart Interactive Chart >
Arena Pharmaceuticals, Inc. (ARNA) Company Bio
Arena Pharmaceuticals is a biopharmaceutical company focused on discovering, developing and commercializing drugs to address unmet medical needs. The company was founded in 1997 and is based in San Diego, California.
Latest ARNA News From Around the Web
Below are the latest news stories about Arena Pharmaceuticals Inc that investors may wish to consider to help them evaluate ARNA as an investment opportunity.
Arena Pharmaceuticals GAAP EPS of -$2.54 misses by $0.31Arena Pharmaceuticals press release (NASDAQ:ARNA): Q4 GAAP EPS of -$2.54 misses by $0.31. Cash, cash equivalents and marketable securities were $0.7B at December 31, 2021 as compared to $1.1B at December 31, 2020... |
Arena Reports Fourth Quarter and Full Year 2021 Financial Results and Key Program UpdatesPARK CITY, Utah, February 23, 2022--Arena Pharmaceuticals today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2021 |
SFO opens criminal probe into collapse of Arena TelevisionThe Serious Fraud Office has opened a criminal investigation into Arena Television, a collapsed broadcaster that worked on the Euro 2020 football tournament and Glastonbury. |
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PARK CITY, Utah, February 17, 2022--Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the Compensation Committee of its Board of Directors granted to 18 new employees 18,527 inducement restricted stock units ("RSUs"). The inducement RSUs have a grant date and vesting commencement date of February 15, 2022 and were granted as inducements material to the new employees entering employment with Arena in accordance with Nasdaq Listing Rule 5635(c)(4). |
Top Merger Stocks Held By Fund Managers, Mid-Q1 2022Each quarter, I spend some time reading Form 13F filings from hedge funds that specialize in merger arbitrage, documenting, and then analyzing which M&A stocks the funds have bought and which ones they haven't. I then compile the top 10 stocks held in these funds and share the results with... |
ARNA Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | N/A |
| 1-year | N/A |
| 3-year | 47.35% |
| 5-year | 113.29% |
| YTD | N/A |
| 2023 | N/A |
| 2022 | 0.00% |
| 2021 | 20.97% |
| 2020 | 69.15% |
| 2019 | 16.61% |
Continue Researching ARNA
Want to see what other sources are saying about Arena Pharmaceuticals Inc's financials and stock price? Try the links below:Arena Pharmaceuticals Inc (ARNA) Stock Price | Nasdaq
Arena Pharmaceuticals Inc (ARNA) Stock Quote, History and News - Yahoo Finance
Arena Pharmaceuticals Inc (ARNA) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...